These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 14612363)

  • 1. The potential of recombinant surfactant protein D therapy to reduce inflammation in neonatal chronic lung disease, cystic fibrosis, and emphysema.
    Clark H; Reid K
    Arch Dis Child; 2003 Nov; 88(11):981-4. PubMed ID: 14612363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Untapped therapeutic potential of surfactant proteins: is there a case for recombinant SP-D supplementation in neonatal lung disease?
    Clark HW
    Neonatology; 2010 Jun; 97(4):380-7. PubMed ID: 20551708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The present status of exogenous surfactant for the newborn.
    Curley AE; Halliday HL
    Early Hum Dev; 2001 Mar; 61(2):67-83. PubMed ID: 11223270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inherited disorders of neonatal lung diseases.
    Yurdakök M
    Turk J Pediatr; 2004; 46(2):105-14. PubMed ID: 15214737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surfactant proteins A and D in pulmonary diseases of preterm infants.
    Bersani I; Speer CP; Kunzmann S
    Expert Rev Anti Infect Ther; 2012 May; 10(5):573-84. PubMed ID: 22702321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthetic surfactants with SP-B and SP-C analogues to enable worldwide treatment of neonatal respiratory distress syndrome and other lung diseases.
    Johansson J; Curstedt T
    J Intern Med; 2019 Feb; 285(2):165-186. PubMed ID: 30357986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of exogenous surfactant therapy on levels of pulmonary surfactant proteins A and D in preterm infants with respiratory distress syndrome.
    Bae YM; Bae CW; Oh MH; Lee SH; Woo KM; Jung KB
    J Perinat Med; 2009; 37(5):561-4. PubMed ID: 19492923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intratracheal recombinant surfactant protein d prevents endotoxin shock in the newborn preterm lamb.
    Ikegami M; Carter K; Bishop K; Yadav A; Masterjohn E; Brondyk W; Scheule RK; Whitsett JA
    Am J Respir Crit Care Med; 2006 Jun; 173(12):1342-7. PubMed ID: 16556693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolution of pulmonary surfactants for the treatment of neonatal respiratory distress syndrome and paediatric lung diseases.
    Mazela J; Merritt TA; Gadzinowski J; Sinha S
    Acta Paediatr; 2006 Sep; 95(9):1036-48. PubMed ID: 16938747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deficient hydrophilic lung surfactant proteins A and D with normal surfactant phospholipid molecular species in cystic fibrosis.
    Postle AD; Mander A; Reid KB; Wang JY; Wright SM; Moustaki M; Warner JO
    Am J Respir Cell Mol Biol; 1999 Jan; 20(1):90-8. PubMed ID: 9870921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New synthetic surfactants: the next generation?
    Pfister RH; Soll RF
    Biol Neonate; 2005; 87(4):338-44. PubMed ID: 15985757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein containing synthetic surfactant versus animal derived surfactant extract for the prevention and treatment of respiratory distress syndrome.
    Pfister RH; Soll RF; Wiswell T
    Cochrane Database Syst Rev; 2007 Jul; (3):CD006069. PubMed ID: 17636826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deficiencies in lung surfactant proteins A and D are associated with lung infection in very premature neonatal baboons.
    Awasthi S; Coalson JJ; Yoder BA; Crouch E; King RJ
    Am J Respir Crit Care Med; 2001 Feb; 163(2):389-97. PubMed ID: 11179112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inflammation and surfactant.
    Meyer KC; Zimmerman JJ
    Paediatr Respir Rev; 2002 Dec; 3(4):308-14. PubMed ID: 12457601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Colfosceril palmitate. A review of the therapeutic efficacy and clinical tolerability of a synthetic surfactant preparation (Exosurf Neonatal) in neonatal respiratory distress syndrome.
    Dechant KL; Faulds D
    Drugs; 1991 Nov; 42(5):877-94. PubMed ID: 1723378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The surfactant system protects both fetus and newborn.
    Hallman M
    Neonatology; 2013; 103(4):320-6. PubMed ID: 23736009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome.
    Yost CC; Soll RF
    Cochrane Database Syst Rev; 2000; (2):CD001456. PubMed ID: 10796266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exogenous surfactant treatments for neonatal respiratory distress syndrome and their potential role in the adult respiratory distress syndrome.
    Merritt TA; Hallman M; Spragg R; Heldt GP; Gilliard N
    Drugs; 1989 Oct; 38(4):591-611. PubMed ID: 2684594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SP-D loaded PLGA nanoparticles as drug delivery system for prevention and treatment of premature infant's lung diseases.
    Attias Cohen S; Kingma PS; Whitsett JA; Goldbart R; Traitel T; Kost J
    Int J Pharm; 2020 Jul; 585():119387. PubMed ID: 32473376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural requirements for SP-D function in vitro and in vivo: therapeutic potential of recombinant SP-D.
    Clark H; Reid KB
    Immunobiology; 2002 Sep; 205(4-5):619-31. PubMed ID: 12396020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.